Abcellera Biologics Inc
$ 5.71
0.35%
31 Jul - close price
- Market Cap 1,737,586,000 USD
- Current Price $ 5.71
- High / Low $ 5.87 / 5.51
- Stock P/E N/A
- Book Value 3.09
- EPS -0.51
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.10 %
- ROE -0.15 %
- 52 Week High 8.44
- 52 Week Low 2.75
About
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Analyst Target Price
$10.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-02-24 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-04 | 2024-08-06 | 2024-05-07 | 2024-02-20 | 2023-11-02 | 2023-08-03 |
| Reported EPS | -0.14 | -0.03 | -0.19 | -0.12 | -0.15 | -0.12 | -0.17 | -0.13 | -0.14 | -0.16 | -0.1 | -0.11 |
| Estimated EPS | -0.2 | -0.144 | -0.16 | -0.17 | -0.14 | -0.1471 | -0.13 | -0.14 | -0.16 | -0.12 | -0.13 | -0.12 |
| Surprise | 0.06 | 0.114 | -0.03 | 0.05 | -0.01 | 0.0271 | -0.04 | 0.01 | 0.02 | -0.04 | 0.03 | 0.01 |
| Surprise Percentage | 30% | 79.1667% | -18.75% | 29.4118% | -7.1429% | 18.4228% | -30.7692% | 7.1429% | 12.5% | -33.3333% | 23.0769% | 8.3333% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.17 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ABCL
2026-07-30 17:39:29
AbCellera Biologics (ABCL) recently announced a collaboration with Vertex Pharmaceuticals for T-cell engagers, receiving $28 million upfront and potential milestones. This deal, along with a previous one with Jazz Pharmaceuticals, validates AbCellera's technology and provides non-dilutive cash, though the company still faces risks from ongoing losses and the need for clinical readouts for its internal programs to prove efficacy. Investors are closely watching for ABCL635 Phase 2 data as a key proof-of-concept event.
2026-07-30 10:39:29
This article analyzes the financial health of Abcellera Biologics Inc (ABCL), ranking it 232 out of 384 in the Biotechnology & Medical Research industry with a financial score of 6.64. The company's financial status is weak with low operating efficiency, despite a significant year-over-year revenue increase of 96.34% to $8.31M and a net profit increase of 5.38%. Various financial metrics such as Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns are also assessed, though specific data for these categories were not disclosed by the company.
2026-07-30 06:40:50
AbCellera Biologics Inc (ABCL) is indicated as 3.8% overvalued according to GuruFocus's GF Value™, though its Price-to-Sales ratio is only slightly above historical median. The company, a clinical-stage biotechnology firm, recently partnered with Vertex Pharmaceuticals, receiving a $28 million upfront payment to co-develop multispecific T-cell engagers. Despite strong valuation and momentum, ABCL's financial profile shows weaknesses in profitability and growth, with a GF Score™ of 62/100, while insider buying signals some confidence in its future.
2026-07-30 06:40:49
AbCellera Biologics (ABCL) experienced a 5.9% stock drop following the announcement of a collaboration with Vertex Pharmaceuticals. This partnership, focused on T-cell engagers for autoimmune diseases, brings AbCellera $28 million upfront and potential milestones, expanding its platform and easing short-term funding risks. The deal, along with a prior one with Jazz Pharmaceuticals, validates AbCellera's technology, though investors remain focused on clinical readouts for internal programs like ABCL635 as key catalysts.
2026-07-30 05:05:03
This article provides a risk assessment for Abcellera Biologics Inc (ABCL), highlighting its beta value of 1.12, indicating higher volatility compared to the S&P 500. The company's risk assessment score is 4.09, ranking it 102 out of 384 in the Biotechnology & Medical Research industry. Key metrics such as maximum drawdown, volatility, return-to-drawdown ratio, and liquidity are detailed, offering insights into the stock's performance and risk profile.
2026-07-29 17:05:03
AbCellera Biologics has partnered with Vertex Pharmaceuticals in a deal worth $28 million upfront to discover and develop multispecific T-cell engagers (TCEs) for autoimmune diseases. AbCellera will lead discovery while Vertex retains development and commercialization rights, with AbCellera eligible for milestone payments and royalties. This collaboration highlights AbCellera's strategy of licensing its TCE platform across various therapeutic areas and strengthens Vertex's growing portfolio in autoimmune disease research.
